Clinical trials: Transplant Patients
Maintenance Liver Transplant Patients With New Onset Diabetes
Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant
The trial is conducted in patients who have received a liver transplant, were prescribed tacrolimus to prevent organ rejection and developed diabetes from 3 month post-transplantation onwards.
- Trial name
- NCT00171717
- Testing
- Cyclosporine - cyclosporine microemulsion
- Volunteers
- 39 people
- Sponsor
- Novartis
Renal Transplantation, Chronic Renal Allograft Failure
Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)
The purpose of this study is to compare renal transplant recipients on cyclosporine maintenance therapy vs. those converted to tacrolimus-based immunosuppression with respect to renal outcomes.
- Trial name
- NCT00637143
- Testing
- Tacrolimus, Cyclosporine
- Where
- 13 sites in Canada
- Volunteers
- 107 people
- Sponsor
- Astellas Pharma Inc
Graft-Versus-Host Disease
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
- Trial name
- NCT00806208
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- MedImmune LLC
Lymphoma
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
- Trial name
- NCT00948090
- Testing
- IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
- Where
- 42 sites in United States, Canada
- Volunteers
- 207 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Kidney Transplantation
Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation
The purpose of this study is to develop and validate a questionnaire to assess the quality of life when the recipients of kidney transplantation switched their medication from tacrolimus twice daily (BID regimen) to Advagraf…
- Trial name
- NCT03623217
- Testing
- Qualitative interviews with participants
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Astellas Pharma Korea, Inc.
Cutaneous Warts
bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients
As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable…
- Trial name
- NCT00644579
- Testing
- bLAC
- Where
- 5 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- NatImmune A/S
Donor Site Complication
TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Primary objective: 1. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) for Phase I in terms of Incidence of treatment-related AEs and SAEs (including infections and bleeding) 2.
- Trial name
- NCT02737748
- Testing
- TWB-103 Group
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 48 people
- Sponsor
- Transwell Biotech Co., Ltd.
Congenital Pseudarthrosis of Tibia
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.
The purpose of this study is to assess the efficacy and safety of NVD003 in pediatric participants with unilateral Congenital Pseudarthrosis of the Tibia (CPT) compared with iliac crest bone graft (ICBG) at 12 months post graft…
- Trial name
- NCT07112443
- Testing
- NVD003, Iliac Crest Bone Graft
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 12 people
- Sponsor
- Novadip Biosciences
Graft Rejection, Kidney Transplantation
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
- Trial name
- CRAF (NCT00510913)
- Testing
- tacrolimus
- Where
- 18 sites in United States
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Abdominal Aortic Aneurysms
Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
The primary goal of the study is to assess the safety and performance of the Treovance device in subjects with infrarenal aortic aneurysms, specifically to evaluate if the diseased pathology can be treated with an acceptable…
- Trial name
- NCT01328197
- Testing
- Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bolton Medical
Respiratory Syncytial Virus Infections
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients
- Trial name
- NCT01065935
- Testing
- ALN-RSV01, Normal Saline
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 87 people
- Sponsor
- Alnylam Pharmaceuticals
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Degenerative Disc Disease
TELAMON P™ Implant/INFUSE® Bone Graft/CD HORIZON® Spinal System Pilot Study
The purpose of this pilot study is to evaluate the feasibility of the implant ( TELAMON P™ Implant/INFUSE Bone Graft System used in conjunction with the CD HORIZON® Spinal System) as a method of facilitating lumbar spinal fusion…
- Trial name
- NCT01491516
- Testing
- TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System
- Volunteers
- 30 people
- Sponsor
- Medtronic Spinal and Biologics
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia)
PRAISE-IR Versus CIBMTR Controls
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07717164
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Miltenyi Biomedicine GmbH
Renal Failure Chronic Requiring Hemodialysis
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Compare the HeRO Vascular Access Device to a conventional ePTFE graft.
- Trial name
- NCT00890045
- Testing
- HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft
- Where
- 11 sites in United States
- Volunteers
- 72 people
- Sponsor
- Merit Medical Systems, Inc.
Kidney Transplantation
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients
To prove non-inferiority of MR4 to Prograf by evaluating the efficacy and safety of Prograf and MR4 in new kidney transplant recipients
- Trial name
- NCT00720265
- Testing
- Prograf, MR4
- Where
- 2 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- Astellas Pharma Inc
Renal Transplantation
Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
Calcineurin inhibitors (CNI), a potent immunosuppressive drug used in kidney transplant recipients to prevent graft rejection, may cause renal impairment.
- Trial name
- NCT00332839
- Testing
- Everolimus, Cyclosporin A (CsA), Tacrolimus
- Where
- 11 sites in Germany
- Volunteers
- 93 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
PIONEER-II RCT trial is a prospective, multicenter, randomized, non-inferiority registry trial. 539 subjects from about 40 interventional cardiology centers in China will be enrolled to evaluate In-stent late lumen loss(LLL) as…
- Trial name
- RCT (NCT02698839)
- Testing
- BuMA Supreme, BuMA™
- Where
- China
- Volunteers
- 539 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Kidney Transplantation
A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
This 2 arm study will compare the efficacy and safety of CellCept, combined with low or standard dose tacrolimus plus corticosteroids, in patients with kidney transplants.
- Trial name
- NCT00758602
- Testing
- mycophenolate mofetil, tacrolimus, standard dose, tacrolimus, low dose
- Where
- 6 sites in China
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation
Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
Investigate whether concomitant treatment with intravenous immunoglobulin (IVIG) can alter the pharmacokinetics and pharmacodynamics of LFG316 to an extent which would necessitate dose adaptation for LFG316 in pre-sensitized…
- Trial name
- NCT02878616
- Testing
- LFG316, IVIG
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals